Kineta, Inc. (Nasdaq: KA) is delighted to announce that the company will be presenting its ground-breaking VISTA clinical program at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida.
Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, is set to deliver a poster presentation that will showcase new preclinical data on VISTA expression and its potential to be used as a biomarker in patients with advanced solid tumors. Don’t miss this incredible opportunity to learn more about Kineta’s unique immunotherapies and how they could revolutionize the treatment of cancer.
Kineta is a biotechnology company on the cutting edge of transforming cancer therapy and patient lives. With a mission to develop next-generation immunotherapies, Kineta has leveraged its expertise in innate immunity to discover and develop potentially revolutionary immunotherapies that overcome the major challenges associated with cancer treatment. Powered by the Nasdaq, Kineta is leading the charge to provide groundbreaking solutions to this devastating disease.
KVA12123, formerly known as KVA12.1, is an innovative, fully human IgG1 monoclonal antibody immunotherapy that has the potential to revolutionize the treatment of cancer. By specifically targeting VISTA through a unique epitope, KVA12123 may be a powerful treatment for many types of cancer, including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian. This could be a life-saving therapy for those affected by these conditions, and a major advance in the field of oncology.